{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:22:02Z","timestamp":1772119322441,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05733-y","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:31:21Z","timestamp":1748928681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA PET-detected mesorectal nodal metastasis: treatment outcomes and clinical implications"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-569X","authenticated-orcid":false,"given":"Rashid K.","family":"Sayyid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zizo","family":"Al-Daqqaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shideh","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Grace","family":"Cockburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ur","family":"Metser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"5733_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1148\/radiol.211836","volume":"304","author":"A Basso Dias","year":"2022","unstructured":"Basso Dias A, Finelli G, Bauman G, Veit-Haibach P, Berlin A, Ortega C et al (2022) Impact of 18F-DCFPyL PET on staging and treatment of unfavorable intermediate or High-Risk prostate Cancer. Radiology 304:600\u2013608","journal-title":"Radiology"},{"key":"5733_CR2","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D et al (2021) Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase 3, multicenter study. Clin Cancer Res 27:3674\u20133682","journal-title":"Clin Cancer Res"},{"key":"5733_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S et al (2021) A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate-Specific membrane antigen PET\/CT with 18F-DCFPyL in prostate Cancer patients (OSPREY). J Urol 206:52\u201361","journal-title":"J Urol"},{"key":"5733_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1148\/radiol.211824","volume":"303","author":"U Metser","year":"2022","unstructured":"Metser U, Zukotynski K, Mak V, Langer D, MacCrostie P, Finelli A et al (2022) Effect of 18F-DCFPyL PET\/CT on the management of patients with recurrent prostate cancer: results of a prospective multicenter registry trial. Radiology 303:414\u2013422","journal-title":"Radiology"},{"key":"5733_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bju.16123","volume":"132","author":"RK Sayyid","year":"2023","unstructured":"Sayyid RK, Bernardino R, Al-Daqqaq Z, Tiwari R, Cockburn J, Vijayakanthan S et al (2023) Mesorectal nodal metastasis with seminal vesicle invasion in biochemically recurrent prostate cancer. BJU Int 132:664\u2013670","journal-title":"BJU Int"},{"key":"5733_CR6","doi-asserted-by":"publisher","first-page":"722430","DOI":"10.3389\/fonc.2021.722430","volume":"11","author":"S Young","year":"2021","unstructured":"Young S, Metser U, Sistani G, Langer DL, Bauman G (2021) Establishing a provincial registry for recurrent prostate cancer: providing access to PSMA PET\/CT in ontario, Canada. Front Oncol 11:722430","journal-title":"Front Oncol"},{"key":"5733_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"MS Cookson","year":"2007","unstructured":"Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D\u2019Amico AV, Dmochowski RR et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540\u2013545","journal-title":"J Urol"},{"key":"5733_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/cncr.23139","volume":"112","author":"MC Abramowitz","year":"2008","unstructured":"Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A et al (2008) The Phoenix definition of biochemical failure predicts overall survival in patients with prostate cancer. Cancer 112:55\u201360","journal-title":"Cancer"},{"key":"5733_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M et al (2018) Prostate Cancer molecular imaging standardized evaluation (PROMISE): proposed MiTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med 59:469\u2013478","journal-title":"J Nucl Med"},{"key":"5733_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10350-004-6656-4","volume":"46","author":"R Topor","year":"2003","unstructured":"Topor R, Acland R, Kolodko V, Galandiuk S (2003) Mesorectal lymph nodes: their location and distribution within the mesorectum. Dis Colon Rectum 46:779\u2013785","journal-title":"Dis Colon Rectum"},{"key":"5733_CR11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K et al (2016) Trial design and objectives for Castration-Resistant prostate cancer: updated recommendations from the prostate Cancer clinical trials working group 3. J Clin Oncol 34:1402\u20131418","journal-title":"J Clin Oncol"},{"key":"5733_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","volume":"76","author":"JM Michalski","year":"2010","unstructured":"Michalski JM, Lawton C, El Naqa I, Ritter M, O\u2019Meara E, Seider MJ et al (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76:361\u2013368","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5733_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.radonc.2021.07.018","volume":"163","author":"RM Glicksman","year":"2021","unstructured":"Glicksman RM, Loblaw A, Morton G, Szumacher E, Chung HT, Vesprini D et al (2021) Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high-risk prostate cancer: Long-term results from a prospective clinical trial. Radiother Oncol 163:21\u201331","journal-title":"Radiother Oncol"},{"key":"5733_CR14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/j.1553-2712.2011.01185.x","volume":"18","author":"JC Stoltzfus","year":"2011","unstructured":"Stoltzfus JC (2011) Logistic regression: a brief primer. Acad Emerg Med 18:1099\u20131104","journal-title":"Acad Emerg Med"},{"key":"5733_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650\u2013659","journal-title":"JAMA Oncol"},{"key":"5733_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A et al (2018) Surveillance of metastasis-directed therapy for oligometastatic cancer recurrence: A prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446\u2013453","journal-title":"J Clin Oncol"},{"key":"5733_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/EVIDoa2200195","volume":"2","author":"LA Gharzai","year":"2023","unstructured":"Gharzai LA, Jiang R, Jaworski EM, Rivera KM, Dess RT, Jackson WC et al (2023) Meta-Analysis of candidate surrogate end points in advanced prostate Cancer. NEJM Evid 2:4","journal-title":"NEJM Evid"},{"key":"5733_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138\u2013148","journal-title":"N Engl J Med"},{"key":"5733_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","volume":"18","author":"DJ George","year":"2020","unstructured":"George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovsky J et al (2020) Treatment patterns and outcomes in patients with metastatic Castration-resistant prostate Cancer in a Real-world clinical practice setting in the united States. Clin Genitourin Cancer 18:284\u2013294","journal-title":"Clin Genitourin Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05733-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:50:36Z","timestamp":1767966636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05733-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5733"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05733-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5869163\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Appropriate ethics approval was obtained from the University Health Network research ethics board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Given the nature of the study, patient consent was not required by the institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentations"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"352"}}